title: Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin.
abstract: Reduced effectiveness of the most common antiplatelet drug, acetylsalicylic acid (ASA, aspirin), in diabetes mellitus has been associated with a lowered platelet sensitivity to ASA and related to glycemic control in diabetic patients. Our objectives were (a) to monitor the chemical background of how chronic hyperglycemia affects platelet response to ASA in diabetes and (b) to study a chemical competition between the amount of bound acetyl residues and the extent of protein glycation in blood platelets. Using whole-blood impedance aggregometry and platelet function analyzer (PFA-100) we observed a reduced platelet response to ASA in diabetic patients (14% vs. 79% for PFA-100 collagen-epinephrine occlusion time) and an association between the index of glycemic control and platelet refractoriness to ASA (r(S) = -0.378). Impaired platelet response to ASA was related to enhanced platelet protein glycation (3.6+/-0.4 in diabetes vs. 2.3+/-0.4 micromol fructosamine/microg protein in control) and reduced incorporation of acetyl residue into proteins of platelets from diabetic patients (47.4+/-2.0 in control vs. 33.1+/-0.7 micromol acetyl/microg protein in diabetic subjects). Incubation of blood platelets with increasing concentrations of glucose and ASA under in vitro conditions led to excessive modification in protein amino groups: glucose and ASA competed with each other in the course of nonenzymatic modifications, glycosylation, or acetylation, and their contributions to the occupancy of protein amino groups (R2 = 0.22 for glucose, R2 = 0.43 for ASA) were dependent upon the concentrations of glucose and ASA. Overall the effects of high glucose and high ASA on the overall occupancy of protein free amino groups are not additive. While at higher concentrations ASA overcomes the effects of hyperglycemia and retards glycation, high glucose makes acetylation less efficient, and therefore the resultant chemical modification becomes greatly reduced. In conclusion, diminished susceptibility of various platelet proteins and receptors on blood platelet membranes to acetylation and high ambient glucose might underlie the apparently differentiated sensitivity of blood platelets to ASA and determine platelet "insensitivity to aspirin" in diabetic patients.
authors.affiliation: Department of Hemostasis and Hemostatic Disorders, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland. cwatala@csk.am.lodz.pl
authors.forename: Cezary
authors.initials: C
authors.lastname: Watala
authors.forename: Justyna
authors.initials: J
authors.lastname: Pluta
authors.forename: Jacek
authors.initials: J
authors.lastname: Golanski
authors.forename: Marcin
authors.initials: M
authors.lastname: Rozalski
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Czyz
authors.forename: Zygmunt
authors.initials: Z
authors.lastname: Trojanowski
authors.forename: Józef
authors.initials: J
authors.lastname: Drzewoski
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage* / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004837:Epinephrine / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D006943:Hyperglycemia; D008297:Male; D008565:Membrane Proteins / Q000097:blood / Q000737:chemistry / Q000187:drug effects; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D008565:Membrane Proteins; D010975:Platelet Aggregation Inhibitors; D003094:Collagen; D005947:Glucose; D001241:Aspirin; D004837:Epinephrine
references.citation: Diabetes. 1992 Mar;41(3):261-6
references.pmid: 1551486
references.citation: J Am Coll Cardiol. 2003 Mar 19;41(6):961-5
references.pmid: 12651041
references.citation: Thromb Res. 1989 Dec 15;56(6):763-6
references.pmid: 2633404
references.citation: Biochem Pharmacol. 2001 Nov 15;62(10):1399-408
references.pmid: 11709200
references.citation: Can J Physiol Pharmacol. 1994 Mar;72(3):295-303
references.pmid: 8069776
references.citation: Invest Ophthalmol Vis Sci. 1989 Jun;30(6):1120-6
references.pmid: 2525117
references.citation: Thromb Haemost. 2002 Nov;88(5):711-5
references.pmid: 12428082
references.citation: J Immunol Methods. 1994 Jan 3;167(1-2):121-7
references.pmid: 7905897
references.citation: Anal Biochem. 1985 Oct;150(1):76-85
references.pmid: 3843705
references.citation: Thromb Res. 2003 Mar 15;109(5-6):299-306
references.pmid: 12818254
references.citation: Am J Cardiol. 2001 Aug 1;88(3):230-5
references.pmid: 11472699
references.citation: Br Med J. 1976 Apr 24;1(6016):994-6
references.pmid: 1083757
references.citation: Am J Physiol Heart Circ Physiol. 2001 Apr;280(4):H1480-9
references.pmid: 11247757
references.citation: Blood. 1986 Oct;68(4):886-91
references.pmid: 3092890
references.citation: J Pharm Pharmacol. 1997 Mar;49(3):273-6
references.pmid: 9231344
references.citation: Diabetes Care. 2004 May;27(5):1245-6
references.pmid: 15111568
references.citation: Diabetes Care. 1997 May;20(5):832-5
references.pmid: 9135951
references.citation: Biochem J. 1982 Apr 1;203(1):313-21
references.pmid: 7103944
references.citation: Thromb Haemost. 1992 Nov 10;68(5):577-82
references.pmid: 1455404
references.citation: Semin Thromb Hemost. 1998;24(2):195-202
references.pmid: 9579642
references.citation: Stroke. 1992 Jun;23(6):851-4
references.pmid: 1595104
references.citation: Acta Physiol Pharmacol Latinoam. 1986;36(3):313-6
references.pmid: 3577806
references.citation: Indian J Exp Biol. 1998 Jul;36(7):651-7
references.pmid: 9782780
references.citation: Semin Thromb Hemost. 1991 Oct;17(4):433-8
references.pmid: 1803514
references.citation: Biochem Biophys Res Commun. 1994 Mar 15;199(2):683-6
references.pmid: 8135810
references.citation: Platelets. 1999;10(1):52-60
references.pmid: 16801071
references.citation: Ophthalmic Res. 1993;25(6):349-54
references.pmid: 8309673
references.citation: Thromb Res. 2002 Sep 15;107(6):319-23
references.pmid: 12565718
references.citation: Biochem Pharmacol. 1993 Mar 24;45(6):1343-9
references.pmid: 8385461
references.citation: J Thromb Haemost. 2003 Aug;1(8):1710-3
references.pmid: 12911581
references.citation: Diabetes Care. 2003 Dec;26(12):3264-72
references.pmid: 14633812
references.citation: Exp Eye Res. 1999 Jul;69(1):109-15
references.pmid: 10375455
references.citation: Eur J Haematol. 1993 May;50(5):264-8
references.pmid: 8319788
references.citation: J Thromb Thrombolysis. 2002 Feb;13(1):49-56
references.pmid: 11994560
references.citation: Thromb Res. 2004;113(2):101-13
references.pmid: 15115665
references.citation: BMJ. 2003 Jan 11;326(7380):82-3
references.pmid: 12521973
references.citation: J Lab Clin Med. 1986 Oct;108(4):286-93
references.pmid: 3760670
references.citation: J Mol Med (Berl). 2002 Dec;80(12):796-801
references.pmid: 12483465
references.citation: Ann Thorac Surg. 1994 Apr;57(4):981-6
references.pmid: 8166553
references.citation: Diabetes Care. 2004 Jan;27 Suppl 1:S72-3
references.pmid: 14693931
references.citation: Diabetes Care. 2003 Jul;26(7):2181-8
references.pmid: 12832332
references.citation: Nat Struct Biol. 1995 Aug;2(8):637-43
references.pmid: 7552725
references.citation: Circulation. 1999 Jan 19;99(2):224-9
references.pmid: 9892587